Please use this identifier to cite or link to this item:
|Title:||Biochemical effects of phosphate-containing replacement fluid for continuous venovenous hemofiltration.|
|Authors:||Chua, Horng-Ruey;Baldwin, Ian;Ho, Lisa;Collins, Allison L;Allsep, Helen;Bellomo, Rinaldo|
|Affiliation:||Department of Intensive Care, Austin Health, Melbourne, Vic., Australia.|
|Citation:||Blood Purification 2012; 34(3-4): 306-12|
|Abstract:||To examine biochemical effects of phosphate-containing replacement fluid (Phoxilium(®)) for continuous venovenous hemofiltration (CVVH).Retrospective comparison of respective serum biochemistry with sequential use of Accusol™ and Phoxilium, each over 48 h of CVVH.We studied 15 critically ill patients. Accusol was switched to Phoxilium after 5 (4-8) days of CVVH. Respective serum biochemistry after 36-42 h of Accusol versus Phoxilium were: phosphate 1.02 (0.82-1.15) versus 1.44 (1.23-1.78) mmol/l, ionized calcium 1.28 (1.22-1.32) versus 1.12 (1.06-1.21) mmol/l, bicarbonate 24 (23-25) versus 20 (19-22) mmol/l, base excess 0 (-2 to 1) versus -4 (-6 to -3) mmol/l (p < 0.001). Cumulative phosphate intakes during respective periods were 69.6 (56.6-76.6) versus 67.2 (46.6-79.0) mmol (p = 0.45). Plasma strong ion differences were narrower with Phoxilium (p < 0.05), with similar strong ion gaps. No additional intravenous phosphate was given during Phoxilium use. Seven patients had serum phosphate >1.44 mmol/l.Phoxilium versus Accusol use during CVVH effectively prevented hypophosphatemia but contributed to mild hyperphosphatemia, and is associated with relative hypocalcemia and metabolic acidosis.|
|Internal ID Number:||23235269|
Acute Kidney Injury.blood.complications.therapy
Hypophosphatemia.etiology.prevention & control
Intensive Care Units
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.